New vaccine targets group b strep in seniors
NCT ID NCT05782179
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This early-stage trial tested a new vaccine against Group B Streptococcus (GBS) in 90 healthy adults aged 55 to 75. Participants received three doses of the vaccine or a placebo, and researchers monitored safety and immune response for six months. The goal is to see if the vaccine is safe and triggers a strong immune defense against GBS, which can cause severe infections in older adults.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Group B Streptococcus vaccine (GBS-NN/NN2 with alhydrogel adjuvant)
What this could lead to
If successful, this could lead to a vaccine that protects older adults from Group B Strep infections, which can cause serious illness.
What could go wrong
This is an early Phase 1 trial with only 90 participants, so safety and immune response are still being tested. It may not work in larger, more diverse groups.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University Hospital Ghent - Centrum voor Vaccinologie (CEVAC) department
Ghent, 9000, Belgium